Distinguished in Pulmonary Fibrosis

Dr. Yolanda Mageto

Pulmonary Medicine | Transplant Surgery
3410 Worth St, Ste 250, 
Dallas, TX 
Offers Telehealth
34 Years of Experience
Distinguished in Pulmonary Fibrosis
3410 Worth St, Ste 250, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Yolanda Mageto is a Pulmonary Medicine specialist and a Transplant Surgeon in Dallas, Texas. Dr. Mageto has been practicing medicine for over 34 years and is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, and Hypersensitivity Pneumonitis.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles and participated in 1 clinical trial in the study of Pulmonary Fibrosis.

Graduate Institution
Washington University School Of Medicine, 1991
Residency
Internal Medicine, Parkland Health & Hospital System
Specialties
Pulmonary Medicine
Transplant Surgery
Licenses
Critical Care Medicine in VT
Board Certifications
American Board Of Internal Medicine
Fellowships
Pulmonary/Critical Care, University of Washington School of Medicine
Pulmonary Critical Care, University of Washington Medical Center
Hospital Affiliations
Baylor Scott And White All Saints Medical Center
Baylor Scott & White Heart & Vascular Hospital - Dallas
Baylor University Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Baylor Scott & White Advanced Lung Disease Specialists Dallas
3410 Worth St, Ste 250, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis
Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis
Enrollment Status: Withdrawn
Publish Date: February 01, 2022
Intervention Type: Drug
Study Drug: Fasenra
Study Phase: Phase 4
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

12 Total Publications

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
Journal: American journal of respiratory and critical care medicine
Published: January 04, 2024
Similar Doctors
Elite in Pulmonary Fibrosis
Dr. Chad A. Newton
Pulmonary Medicine
Elite in Pulmonary Fibrosis
Dr. Chad A. Newton
Pulmonary Medicine

University Of Texas Southwestern Medical Center At Dallas

5323 Harry Hines Blvd, 
Dallas, TX 
 (29.9 miles away)
216-648-0600
Languages Spoken:
English
See accepted insurances

Chad Newton is a Pulmonary Medicine provider in Dallas, Texas. Dr. Newton is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Lung Transplant.

Elite in Pulmonary Fibrosis
Dr. Susan Mathai
Pulmonary Medicine
Elite in Pulmonary Fibrosis
Dr. Susan Mathai
Pulmonary Medicine

Baylor Scott & White Advanced Lung Disease Specialists Dallas

3410 Worth St, Ste 250, 
Dallas, TX 
 (33.2 miles away)
972-449-0540
Experience:
16+ years
Languages Spoken:
English
See accepted insurances

Susan Mathai is a Pulmonary Medicine provider in Dallas, Texas. Dr. Mathai has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Lung Transplant.

Distinguished in Pulmonary Fibrosis
Dr. Traci N. Adams
Pulmonary Medicine
Distinguished in Pulmonary Fibrosis
Dr. Traci N. Adams
Pulmonary Medicine

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (29.5 miles away)
214-645-8600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Traci Adams is a Pulmonary Medicine provider in Dallas, Texas. Dr. Adams is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Hypersensitivity Pneumonitis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Endoscopy, and Lung Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mageto's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile